Current trendNatural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantationHistoire naturelle et traitement de la récidive du carcinome hépatocellulaire après transplantation hépatique
Introduction
Hepatocellular carcinoma (HCC) is the commonest primary malignant disease of the liver. Worldwide, it is the sixth leading cause of cancer and the third leading cause of cancer death [1]. Incidence has risen steadily in Europe, doubling in France in the last two decades [2].
Liver transplantation is the ideal treatment for HCC in cirrhosis because in addition to resection of the tumor, any malignant and/or pre-malignant foci, which could be present but not necessarily visible in the adjacent parenchyma, are removed. Until the early 1990s, the rate of disease recurrence following liver transplantation was high because transplantation was proposed for any stage of tumor dissemination. Indicators predictive of recurrence were then rapidly identified enabling an evidence-based selection of candidates with a low probability of recurrence. Using the Milan criteria, widely applied in Europe, the overall probability of survival at five years is relatively close to that observed for cirrhosis without HCC.
In France, the number of HCC patients waiting for liver transplantation has doubled in the last five years (135 candidates in 2002 and 323 in 2007). This indication is becoming one of the more prominent for liver transplantation (12.8% of the activity at enrolment in 2002 and 24% in 2007). At the present time, the rate of recurrence five years after liver transplantation is to the order of 10% to 20% [3], [4]. As the activity level for this indication increases, transplantation teams will be called upon to provide care for a growing number of patients with recurrent HCC. While the natural history and appropriate diagnostic and management practices are relatively well defined for HCC [5], data are scarce concerning the characteristic features and treatment modalities for recurrent HCC after liver transplantation.
Section snippets
Evolving risk of recurrence
In the past, the rates of recurrence after liver transplantation have varied greatly, depending on the series reported, but with a steady trend toward lower rates in recent years (Table 1). Before 1993, reported rates were high, to the order of 50%, and had a direct impact on survival. This situation arose because liver transplantation was proposed for patients with large or diffuse non-resectable tumors [6], [7]. As early as 1993, sensitivity analysis focusing on sub-groups of patients with
Adjuvant/neoadjuvant chemotherapy
Several adjuvant/neoadjuvant chemotherapy protocols, adjusted to the real stage of HCC dissemination found on the liver explant, offer attractive therapeutic potential. Considering the low rate of recurrence observed in recent series, it would be logical to propose such protocols for selected sub-populations with a high risk of recurrence. The main problem with this attitude is the safety aspect related to the cumulative toxicity of immunosuppressive and chemotherapy drugs.
Licartin, a
Conclusion
Within five years after their liver transplantation for HCC, 10% to 20% of the recipients with develop recurrent HCC. The overall prognosis of recurrent HCC is poor with fatal outcome within one year of diagnosis. An analysis of the natural history of recurrent HCC identifies several sub-populations with a better prognosis, defined more on the basis of time from liver transplantation to recurrence than on tumor localization. Expressed in terms of survival, the best prognosis is achieved with
Conflict of interests
None.
References (80)
- et al.
Incidence of gastrointestinal cancers in France
Gastroenterol Clin Biol
(2004) - et al.
Liver transplantation for hepatocellular carcinoma
Gastroenterology
(2005) - et al.
Novel advancements in the management of hepatocellular carcinoma in 2008
J Hepatol
(2008) - et al.
Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
Hepatology
(2001) - et al.
Predicting the risk of tumor recurrence following transplantation for hepatocellular carcinoma
Hepatology
(1997) - et al.
Very late recurrence of hepatocellular carcinoma after liver transplantation: Case report and literature review
Transplant Proc
(2006) - et al.
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis
Hepatology
(2001) - et al.
Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma
J Hepatol
(2001) - et al.
Needle track metastasis of primary liver carcinoma after percutaneous needle aspiration
Am J Gastroenterol
(2002) - et al.
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma
Am J Transplant
(2005)